ASPA and Canavan disease: In vivo gene therapy for leukodystrophies began with an AAV trial for Canavan disease, an autosomal recessive leukodystrophy caused by mutations in the ASPA gene, encoding the enzyme aspartoacyclase which functions to degrade N-acetylaspartate (NAA) in the brain (Janson et al., 2002).